Montrouge, France, June 26, 2019 DBV Technologies Announces Appointment of Pharis Mohideen, M.D., as Chief Medical Officer Dr. Mohideen brings extensive experience in clinical drug development Dr. Hugh Sampson to continue serving as Chief Scientific Officer DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Pharis Mohideen, M.D., as its Chief Medical Officer (CMO), effective July 22, 2019. Dr. Mohideen will serve as a member of the Executive Committee and report to Daniel Tassé, Chief Executive Officer of DBV Technologies. Following Dr. Mohideen`s start date, Dr. Hugh Sampson, who...
|